ClinicalTrials.Veeva

Menu

Ovarian Function and Gynecological Profile of Patients Carrying a Pathogenic Variant of the HNF1B Gene (GYN-HNF1)

T

Toulouse University Hospital

Status

Completed

Conditions

Genital Diseases, Female

Treatments

Biological: blood sample
Other: Pelvic ultrasound

Study type

Interventional

Funder types

Other

Identifiers

NCT04746053
2020-A02800-39 (Other Identifier)
RC31/20/0124

Details and patient eligibility

About

The main objective of this study is to study the ovarian function of patients with hepatocyte nuclear factor-1beta (HNF1B) abnormality, followed in the reference centers of Toulouse and Paris University Hospitals. The secondary objectives are to know the gynecological profile of these patients.

A dosage of anti-mullerian hormone (AMH) will be added to the usual balance, whatever the phase of the cycle and a pelvic ultrasound will be performed by the same operator by center. Patients will be received in a dedicated consultation to complete a questionnaire on gynecological and obstetric history, as well as their personal and family history. There will be no gynecological examination during this consultation.

Full description

HNF1B mutations can be responsible for genital malformations associated with renal development abnormalities. HNF1b is also a candidate gene involved in the development of the renal tract and the Mullerian system but there is no data in the literature regarding the ovarian function and clinical gynecological profile of these patients.

The main objective of this study is to study the ovarian function of patients with HNF1B abnormality, followed in the reference centers of Toulouse and Paris University Hospitals. The secondary objectives are to know the gynecological profile of these patients.

A dosage of AMH will be added to the usual balance, whatever the phase of the cycle and a pelvic ultrasound will be performed. Patients will be received in a dedicated consultation to complete a questionnaire on gynecological and obstetric history, as well as their personal and family history. There will be no gynecological examination during this consultation.

Enrollment

26 patients

Sex

Female

Ages

12+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Girls from 12 years of age carrying a pathogenic variant of the HNF1 B gene and monitored in the reference center for rare renal diseases
  • Person affiliated or beneficiary of a social security scheme.
  • Free, informed and written consent signed by the participant or her legal representative if a minor patient and the investigator (at the latest on the day of inclusion and before any examination required by the research).

Exclusion criteria

  • Woman unable to answer
  • Pregnant or breastfeeding woman
  • Refusal of participation by the patient or her legal representative
  • Person under a protection system for adults (such as safeguard of justice, guardianship or curatorship)
  • History of chemotherapy, radiotherapy, brachytherapy
  • History of ovarian endometrium

Trial design

Primary purpose

Other

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

26 participants in 1 patient group

patient with a mutation in the HNF1B gene
Other group
Description:
Patient with a mutation in the HNF1B gene and which are followed in the reference centers
Treatment:
Biological: blood sample
Other: Pelvic ultrasound

Trial contacts and locations

3

Loading...

Central trial contact

Catherine PIENKOWSKI, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems